Prostate cancer screening guidelines are medical recommendations that set out when men should start PSA blood testing, how often to repeat it, and when to stop. The American Cancer Society (ACS) revised its guidelines on November 12, 2026. Men at average risk should now take a prostate-specific antigen (PSA) test every two years between ages 50 and 69. Black men and men with a strong family history of prostate cancer should begin earlier, at age 45, and test every year.
What Are the New Prostate Cancer Screening Guidelines?
The new ACS prostate cancer screening guidelines are a set of age and risk-based schedules for PSA testing. They replace the 2010 approach, which asked most average-risk men to decide about screening after talking with their doctors. The ACS now recommends regular screening directly, as long as the clinician explains the benefits, limitations and harms first.
|
Group |
PSA testing schedule |
Approximate tests if every one is completed |
|
Men at average risk |
Every two years, ages 50 to 69 |
10 |
|
Black men |
Every year, ages 45 to 69 |
25 |
|
Men with a father, brother or son diagnosed before age 65, or several close relatives diagnosed at any age |
Every year, ages 45 to 69 |
25 |
|
Non-Black men with one close relative diagnosed at 65 or older |
Every two years, ages 45 to 69 |
13 |
|
Men aged 70 to 74 |
Individual decision with a doctor |
Varies |
|
Men aged 75 to 79 |
Not recommended routinely, although very healthy men may discuss continuing, especially if earlier PSA levels were rising |
Varies |
|
Men aged 80 and older, or men expected to live less than 10 years |
Not recommended |
None |
The last column is my own arithmetic, not an ACS figure. It shows how much the schedule changes with risk. A Black man who follows the guideline from 45 to 69 could take about 25 PSA tests, compared with about 10 for an average-risk man. That difference is large, and it is worth raising with a doctor early so the first test is not delayed.
The ACS also describes this as a “living guideline.” The society says it will keep reviewing new evidence and update the advice periodically, so the schedule above may change again.
Why Has the American Cancer Society Changed Its PSA Testing Advice?
The ACS changed its advice because the evidence for PSA-based screening is now stronger, and doctors now have better ways to avoid unnecessary biopsies and treatment. The society based the update on a systematic evidence review and a modeling study of screening strategies. A volunteer group of clinicians, epidemiologists, biostatisticians and patient representatives then wrote the recommendations.
Dr. Robert Smith, the senior author of the report, said PSA testing remains the cornerstone of detecting prostate cancer early. Dr. Andrew Wolf, a member of the guideline committee, told NPR that PSA screening has been shown to reduce the risk of dying from the disease.
Prostate cancer is among the most commonly diagnosed cancers in men and the second-leading cause of cancer death among men in the United States. The ACS estimates that about 333,830 men will be diagnosed in 2026 and about 36,320 will die from it.
Risk is not shared equally. According to the ACS, Black men have a 67% higher incidence and nearly twice the mortality rate of White men. Dr. William Dahut, the society’s chief scientific officer, said the earlier and more frequent schedule for Black men is meant to help reduce that gap.
Screening has a history of drawing criticism, and the criticism was fair. Past concerns centred on false-positive results, unnecessary biopsies, and treatment of slow-growing cancers that might never have caused harm. The new guideline answers those concerns with a second layer of testing, described below.
One point deserves attention. The U.S. Preventive Services Task Force, an influential federal advisory panel, still endorses individual decision-making rather than routine screening, according to NPR. Two respected bodies therefore currently give different default advice. Men should not read the ACS guideline as the final word from every medical organization, and a conversation with a doctor remains the sensible starting point.
What Does a High PSA Test Result Mean?
A high PSA result means the blood contains more prostate-specific antigen, a protein made by prostate cells, than expected for a man’s age group. It is a signal that more testing is needed. It is not a cancer diagnosis.
Several non-cancerous conditions can raise PSA, including an enlarged prostate, prostate inflammation and urinary infection. Levels can also shift temporarily. Many clinicians suggest avoiding ejaculation and vigorous cycling for a day or two before a test, because both can push the number up. Men who take a 5-alpha reductase inhibitor for prostate enlargement should tell the doctor ordering the test, because these medicines lower PSA readings and can hide a real rise.
The ACS sets these thresholds for further evaluation:
- 3.0 ng/mL or higher for men aged 45 to 69
- 6.5 ng/mL or higher for men aged 70 to 74
The next steps follow a fixed order:
- The doctor repeats the PSA test between two weeks and three months later to confirm the result.
- If the level stays high, the man should be offered a prostate MRI, a validated biomarker test, or both.
- Those results help decide whether a biopsy is actually needed.
This sequence is the practical heart of the update. The PSA test is only the first step, and the follow-up testing gives the doctor more information before recommending a biopsy, an invasive procedure that carries risks such as bleeding and infection.
Does an Early Prostate Cancer Diagnosis Always Require Treatment?
No. Finding prostate cancer does not automatically mean a man needs surgery or radiation. Some prostate cancers grow so slowly that they never cause serious problems during a man’s lifetime.
For men diagnosed with low-risk prostate cancer, the ACS now says active surveillance should be offered as the first management option. Active surveillance means monitoring the cancer with regular PSA tests, imaging and, when appropriate, repeat biopsies. Treatment begins only if the cancer shows signs of becoming more aggressive.
The reason is practical. Treatment can cause urinary incontinence, erectile dysfunction and bowel problems, and a man with a harmless cancer gains nothing from taking on those risks. Dr. Shanthi Sivendran, the ACS interim chief patient officer, described screening as an early warning system. It catches aggressive cancers while lower-risk findings are watched carefully rather than treated at once.
Active surveillance still requires discipline. A man who chooses it commits to every follow-up test, and missing appointments defeats the purpose.
When Should Men Talk to a Doctor About Prostate Cancer Screening?
Men should talk to a doctor before they reach the screening age for their risk group, not after. Age alone does not decide the schedule, and a short conversation can place a man in the correct row of the table above.
Useful points to bring to that appointment:
- Family history. The ACS counts a father, brother or son as a close relative. The age at diagnosis matters as much as the number of relatives affected.
- Race and ancestry. Black men should ask specifically about starting annual testing at 45.
- Medications. Some prostate medicines change PSA readings.
- Coverage. A guideline from a medical society does not by itself decide what an insurer pays for. The ACS advocacy arm has said it will push for coverage of screening and follow-up testing without cost sharing, but coverage rules vary by plan, so asking about out-of-pocket costs for the PSA test, MRI and biomarker tests is reasonable.
Screening is for men without symptoms. Men who have trouble urinating, or who notice blood in their urine or semen, should see a doctor promptly instead of waiting for the next scheduled test.
The practical takeaway is simple. Men should work out which risk group they belong to, learn when testing begins for that group, and make each decision about testing, follow-up and treatment together with their doctor.